Innovative retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Initial clinical trials have revealed substantial reductions in overall mass and improvements in health markers for people with obesity . Experts believe this unique approach may signify a